More importantly, as cGMP signaling is a common signaling pathway in all types of breast cancer and largely independent of the estrogen receptor, progesterone receptor or HER-2 receptor, targeting this pathway is a promising and novel approach to improve triple-negative breast cancer survival rates. The gene discussed is ESR1; the disease is breast carcinoma.